Kissei Pharmaceutical Co. Ltd
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thr… Read more
Kissei Pharmaceutical Co. Ltd (KSPHF) - Total Assets
Latest total assets as of September 2025: $261.12 Billion USD
Based on the latest financial reports, Kissei Pharmaceutical Co. Ltd (KSPHF) holds total assets worth $261.12 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kissei Pharmaceutical Co. Ltd - Total Assets Trend (2005–2025)
This chart illustrates how Kissei Pharmaceutical Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kissei Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Kissei Pharmaceutical Co. Ltd's total assets of $261.12 Billion consist of 43.8% current assets and 56.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.3% |
| Accounts Receivable | $29.65 Billion | 12.2% |
| Inventory | $24.98 Billion | 10.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.65 Billion | 0.7% |
| Goodwill | $242.00 Million | 0.1% |
Asset Composition Trend (2005–2025)
This chart illustrates how Kissei Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kissei Pharmaceutical Co. Ltd's current assets represent 43.8% of total assets in 2025, a decrease from 56.8% in 2005.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2025, down from 21.7% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 12.2% of total assets.
Kissei Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of Kissei Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Kissei Pharmaceutical Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Kissei Pharmaceutical Co. Ltd generates 0.36x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Kissei Pharmaceutical Co. Ltd generates $ 4.90 in net profit.
Kissei Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.57 | 5.50 | 5.18 |
| Quick Ratio | 2.79 | 4.15 | 4.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $86.30 Billion | $ 87.56 Billion | $ 76.26 Billion |
Kissei Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Kissei Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.77 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -6.5% |
| Total Assets | $244.06 Billion |
| Market Capitalization | $666.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kissei Pharmaceutical Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kissei Pharmaceutical Co. Ltd's assets decreased by 6.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kissei Pharmaceutical Co. Ltd (2005–2025)
The table below shows the annual total assets of Kissei Pharmaceutical Co. Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $244.06 Billion | -6.47% |
| 2024-03-31 | $260.93 Billion | +15571.67% |
| 2023-03-31 | $1.66 Billion | -14.87% |
| 2022-03-31 | $1.96 Billion | -19.61% |
| 2021-03-31 | $2.43 Billion | +13.32% |
| 2020-03-31 | $2.15 Billion | +11.30% |
| 2019-03-31 | $1.93 Billion | -2.69% |
| 2018-03-31 | $1.98 Billion | +18.25% |
| 2017-03-31 | $1.68 Billion | -2.55% |
| 2016-03-31 | $1.72 Billion | -99.05% |
| 2015-03-31 | $181.48 Billion | +5.12% |
| 2014-03-31 | $172.65 Billion | +7.89% |
| 2013-03-31 | $160.03 Billion | +10.83% |
| 2012-03-31 | $144.38 Billion | -1.27% |
| 2011-03-31 | $146.25 Billion | -0.53% |
| 2010-03-31 | $147.02 Billion | +4.88% |
| 2009-03-31 | $140.18 Billion | -6.90% |
| 2008-03-31 | $150.57 Billion | -7.96% |
| 2007-03-31 | $163.58 Billion | -6.05% |
| 2006-03-31 | $174.11 Billion | +5.56% |
| 2005-03-31 | $164.94 Billion | -- |